Compared to Dasatinib or PF573228 used alone, when they were used together, the same dose can achieve better inhibitory effect or a relatively lower dose can achieve similar inhibitory effect on cell migration and growth (Figs. 6A–6D), suggesting that it may be beneficial to use FAK and Src inhibitor together in pancreatic cancers. Here, SRC is linked to familial pancreatic carcinoma.